Cargando…

Emerging pharmacologic treatment options for fragile X syndrome

Fragile X syndrome (FXS) is the most common single gene cause of intellectual disability and autism spectrum disorder. Caused by a silenced fragile X mental retardation 1 gene and the subsequent deficiency in fragile X mental retardation protein, patients with FXS experience a range of physical, beh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaefer, Tori L, Davenport, Matthew H, Erickson, Craig A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396424/ https://www.ncbi.nlm.nih.gov/pubmed/25897255 http://dx.doi.org/10.2147/TACG.S35673

Ejemplares similares

Fragile X targeted pharmacotherapy: lessons learned and future directions
por: Erickson, Craig A., et al.
Publicado: (2017)

Developmental studies in fragile X syndrome
por: Razak, Khaleel A., et al.
Publicado: (2020)

Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety
por: Schaefer, Tori L., et al.
Publicado: (2017)

Executive Function in Fragile X Syndrome: A Systematic Review
por: Schmitt, Lauren M., et al.
Publicado: (2019)

Systematic review of pharmacological treatments in fragile X syndrome
por: Rueda, Jose-Ramon, et al.
Publicado: (2009)

GABA(A) Alpha 2,3 Modulation Improves Select Phenotypes in a Mouse Model of Fragile X Syndrome
por: Schaefer, Tori L., et al.
Publicado: (2021)

Fragile X syndrome and fragile X-associated disorders
por: Rajaratnam, Akash, et al.
Publicado: (2017)

Best Practices in Fragile X Syndrome Treatment Development
por: Erickson, Craig A., et al.
Publicado: (2018)

Pharmacological options for pain control in patients with vertebral fragility fractures
por: Tanna, Nuttan Kantilal, et al.
Publicado: (2022)

Neurodevelopment and early pharmacological interventions in Fragile X Syndrome
por: Milla, Luis A., et al.
Publicado: (2023)

Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
por: Budimirovic, Dejan B., et al.
Publicado: (2017)

Closing the Gender Gap in Fragile X Syndrome: Review of Females with Fragile X Syndrome and Preliminary Research Findings
por: Bartholomay, Kristi L., et al.
Publicado: (2019)

Fragile X Syndrome
por: Saldarriaga, Wilmar, et al.
Publicado: (2014)

Delineating Repetitive Behavior Profiles across the Lifespan in Fragile X Syndrome
por: Reisinger, Debra L., et al.
Publicado: (2020)

Mechanisms Driving the Emergence of Neuronal Hyperexcitability in Fragile X Syndrome
por: Bülow, Pernille, et al.
Publicado: (2022)

Fragile X Syndrome in children
por: Acero-Garcés, David O., et al.
Publicado: (2023)

Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes
por: Wang, Hansen, et al.
Publicado: (2015)

Mouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndrome
por: Berman, Robert F, et al.
Publicado: (2014)

Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities
por: Weber, Jayne Dixon, et al.
Publicado: (2019)

Modulation of the GABAergic pathway for the treatment of fragile X syndrome
por: Lozano, Reymundo, et al.
Publicado: (2014)

Behavioral inflexibility in fragile X syndrome: Accounts from caregivers and self-advocates
por: Jones, Angelina, et al.
Publicado: (2023)

Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance
por: Ethridge, Lauren E., et al.
Publicado: (2019)

A neurophysiological model of speech production deficits in fragile X syndrome
por: Schmitt, Lauren M, et al.
Publicado: (2019)

Language across the Lifespan in Fragile X Syndrome: Characteristics and Considerations for Assessment
por: Hoffmann, Anne, et al.
Publicado: (2020)

A Pilot Quantitative Evaluation of Early Life Language Development in Fragile X Syndrome
por: Reisinger, Debra L., et al.
Publicado: (2019)

Molecular Biomarkers in Fragile X Syndrome
por: Zafarullah, Marwa, et al.
Publicado: (2019)

An “Omic” Overview of Fragile X Syndrome
por: Dionne, Olivier, et al.
Publicado: (2021)

Targeted treatments for fragile X syndrome
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2011)

Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
por: Alusi, Ghassan, et al.
Publicado: (2022)

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment
por: Protic, Dragana D., et al.
Publicado: (2022)

Peripheral Amyloid Precursor Protein Derivative Expression in Fragile X Syndrome
por: McLane, Richard D., et al.
Publicado: (2019)

Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome
por: Ethridge, Lauren E., et al.
Publicado: (2017)

Pharmacological Reactivation of the Silenced FMR1 Gene as a Targeted Therapeutic Approach for Fragile X Syndrome
por: Kumari, Daman, et al.
Publicado: (2019)

Descriptive analysis of seizures and comorbidities associated with fragile X syndrome
por: Albizua, Igor, et al.
Publicado: (2022)

Pathological Plasticity in Fragile X Syndrome
por: Martin, Brandon S., et al.
Publicado: (2012)

Emerging pharmacological treatment options for MAFLD
por: Rojas, Ángela, et al.
Publicado: (2022)

Fragile X Syndrome
por: McLennan, Yingratana, et al.
Publicado: (2011)

A resting EEG study of neocortical hyperexcitability and altered functional connectivity in fragile X syndrome
por: Wang, Jun, et al.
Publicado: (2017)

Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome
por: Schmitt, Lauren M., et al.
Publicado: (2022)

Current and Emerging Pharmacological Treatment Options for Dementia
por: Ringman, John M., et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_qteoodep0f1h6uipnftbo253h2